Inhibition by rebamipide of cytokine-induced or lipopolysaccharide-induced chemokine synthesis in human corneal fibroblasts

Fukuda, Ken; Ishida, Waka; Tanaka, Hiroshi; Harada, Yosuke; Fukushima, Atsuki

doi:10.1136/bjophthalmol-2014-305425

Cited by 22 publications

(18 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Japan, it has also been used as an ophthalmic suspension for the treatment of dry eye. Previous studies have reported that rebamipide has an anti-inflammation effect on CECs 4 , corneal fibroblasts 19 , and conjunctival epithelial cells (CjECs) 20 . It has also been reported that rebamipide helps to maintain the microvilli of CECs and CjECs against N-acetylcysteine 21 and the barrier function between CECs 4 .…”

Section: Discussionmentioning

confidence: 99%

Rebamipide promotes lacrimal duct epithelial cell survival via protecting barrier function

Tanaka

Nakayama

Tsukamoto

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Rebamipide promotes lacrimal duct epithelial cell survival via protecting barrier function

Tanaka

Nakayama

Tsukamoto

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…It also exerts anti-inflammatory actions at the ocular surface. It thus increases the secretion of mucin-like substances by corneal epithelial cells Urashima et al, 2012), suppresses cytokine production by corneal epithelial cells (Fukuda et al, 2014) and conjunctival epithelial cells (Tanaka et al, 2013;Ueta et al, 2013), up-regulates barrier function of the corneal epithelium (Kimura et al, 2013;Tanaka et al, 2013), and thereby reduces epithelial punctate keratopathy in the rabbit cornea and conjunctiva (Urashima et al, 2004). In the clinical setting, the administration of rebamipide ophthalmic suspension ameliorates SPK associated with dry eye syndrome (Itakura et al, 2013;Kashima et al, 2012Kashima et al, , 2014Kinoshita et al, 2014Kinoshita et al, , 2013.…”

Section: Superficial Punctate Keratopathymentioning

confidence: 96%

Peptide therapies for ocular surface disturbances based on fibronectin–integrin interactions

Nishida

Inui

Nomizu

2015

Progress in Retinal and Eye Research

View full text Add to dashboard Cite

The condition of the corneal epithelium is a critical determinant of corneal transparency and clear vision. The corneal epithelium serves as a barrier to protect the eye from external insults, with its smooth surface being essential for its optical properties. Disorders of the corneal epithelium include superficial punctate keratopathy, corneal erosion, and persistent epithelial defects (PEDs). The prompt resolution of these disorders is important for minimization of further damage to the cornea. Currently available treatment modalities for corneal epithelial disorders are based on protection of the ocular surface in order to allow natural healing to proceed. PEDs remain among the most difficult corneal conditions to treat, however. On the basis of characterization of the pathobiology of PEDs at the cell and molecular biological levels, we have strived to develop new modes of treatment for these defects. These treatments rely on two key concepts: provision of a substrate, such as the adhesive glycoprotein fibronectin, for the attachment and migration of corneal epithelial cells, and activation of these cells by biological agents such as the combination of substance P and insulin-like growth factor-1 (IGF-1). Central to both approaches is the role of the fibronectin-integrin system in corneal epithelial wound healing. Determination of the minimum amino acid sequences required for the promotion of corneal epithelial wound closure by fibronectin (PHSRN) and by substance P (FGLM-amide) plus IGF-1 (SSSR) has led to the development of peptide eyedrops for the treatment of PEDs that are free of adverse effects of the parent molecules.

show abstract

“…Rebamipide exerted anti-inflammatory effects and promoted epithelial wound healing in animal models. [59][60][61][62][63] Therefore, rebamipide is expected to clinically suppress inflammation. However, an apparent clinical effect has not been identified regarding this issue, and further investigation is required.…”

Section: Clinical Effect Of Rebamipide In Treating Dry Eyementioning

confidence: 99%

Medical Treatment for Dry Eye in Japan

Watanabe

2018

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

The etiology of dry eye has not been clarified. In the United States, the inflammation theory is supported as the main cause of dry eye, whereas the Asia Dry Eye Society has identified tear instability as the main cause. Based on this tear instability concept, the P2Y2 antagonist Diquas and the mucin secretagogue Mucosta were developed and launched in Japan over the last 5 years, and they have been widely prescribed to patients with dry eye. Moreover, Diquas has also been launched in other Asian countries, such as Korea, Thailand, and Vietnam. This report summarizes the efficacy and characteristics of these two eye drops to improve our understanding of dry eye.

show abstract

Inhibition by rebamipide of cytokine-induced or lipopolysaccharide-induced chemokine synthesis in human corneal fibroblasts

Abstract: Rebamipide inhibited the synthesis of chemokines by corneal fibroblasts in association with suppression of NFκB signalling. Rebamipide may therefore prove effective for the treatment of corneal stromal inflammation associated with allergy or bacterial infection.

Cited by 22 publications

References 24 publications

Rebamipide promotes lacrimal duct epithelial cell survival via protecting barrier function

Rebamipide promotes lacrimal duct epithelial cell survival via protecting barrier function

Peptide therapies for ocular surface disturbances based on fibronectin–integrin interactions

Medical Treatment for Dry Eye in Japan

Contact Info

Product

Resources

About